Human placenta hydrolysate as a drug to reduces markers of inflammation in patients with severe COVID-19


DOI: https://dx.doi.org/10.18565/therapy.2020.5.56-68

Maksimov V.A., Tkacheva O.N., Strazhesko I.D., Torshin I.Yu., Gromova O.A., Chuchalin A.G., Lazebnik L.B.

1) Russian Medical Academy of Continuing Postgraduate Education of the Ministry of Healthcare of Russia, Moscow; 2) Gerontological Scientific and Clinical Center of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 3) Federal Research Center «Informatics and management» of Russian Academy of Sciences, Moscow; 4) Big Data Storage and Analysis Center of Lomonosov Moscow State University; 5) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 6) A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
In severe COVID-19, the formation of «cytokine storm» accompanied by an avalanche-like increase in inflammatory markers of IL-1β, IL6, IFN-γ, TNF-α, C-reactive protein (C-RP), ferritin etc. In the absence of adequate treatment the «cytokine storm» increases the risk of death, especially against the background of comorbid pathology.
Purpose: to assess the improvement in the condition of patients with severe COVID-19 when the polypeptide drug Laennec (human placenta hydrolysate; Japan BioProducts Co. Ltd.) is included in the treatment program.
Material and methods. In April–May 2020 14 patients (6 men and 8 women, 39–86 years old) who had a long, stagnant COVID-19 course were monitored. All patients showed a loss of smell, cough with scanty sputum, and signs of conjunctivitis. Chronic diseases (coronary heart disease, type 2 diabetes mellitus, scleroderma) were present in 11 of 14 patients. Depending on the severity of the patient’s condition, Laennec was used for 3–10 days (6 ml per 350 ml of 0.9% NaCl solution, iv, cap.) until a stable remission was achieved. Patients were characterized by liver dysfunction (ALT 11±121 units/L, AST 90,8±87,8 units/L) and a high risk of cytokine storm: ferritin (men) 480–1762 μg/l, ferritin (women) 274,7–493 μg/l, C-RP 5–52,6 mg/l, lymphocytes less than 25% in 10 of 14 patients.
Results. The use of Laennec leads to positive clinical dynamics, a decrease in ferritin levels (in men by -386 μg/L, in women by -80 μg/L; p=0,039), an increase in blood oxygenation to the normal range (p=0,0029), and a decrease in the area of damage lung according to CT data (on average, -10%; p=0,0027), an increase in the relative content of lymphocytes (+8%; p=0,04), normalization of markers of liver dysfunction (AST, ALT), creatinine and systolic blood pressure (p <0,05). All patients recovered within 3–15 days after the start of Laennec administration and were discharged with a negative SARS-CoV-2 virus test.
Conclusion. The inclusion of Laennec in the complex treatment of patients with severe COVID-19 can significantly alleviate the condition of patients. First of all, Laennec should be used in patients with already existing liver pathologies, type 2 diabetes mellitus, coronary heart disease, including against the background of elevated levels of ferritin.
Keywords: COVID-19 therapy, comorbidities, hyperferritinemia, human placenta hydrolyzate, Laennec, markers of inflammation, predictive modeling, data mining
Read entire article

Literature


  1. https://www.vidal.ru/drugs/laennec__13405

  2. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.J Th romb Haemost. 2020; 18(4): 844—47. doi: 10.1111/jth.14768.

  3. Liu C., Jiang Z.C., Shao C.X. et al. [Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study]. Zhonghua Gan Zang Bing Za Zhi. 2020; 28(2): 107—11. doi: 10.3760/cm a.j.issn.1007-3418.2020.02.003.

  4. Громова О.А., Торшин И.Ю. Важность цинка для поддержания активности белков врожденного противовирусного иммунитета: анализ публикаций, посвященных COVID-19. Профилактическая медицина. 2020; 3: 131—139. [Gromova O.A., Torshin I.Yu. The importance of zinc in maintaining the activity of antiviral innate immunity proteins: analysis of publications on COVID-19. Profilakticheskaya meditsina. 2020; 3: 131—139 (In Russ.)]. doi: https://doi.org/10.17116/profmed202023031131.

  5. Стефанюк О.В., Лазебник Л.Б. Поражения органов пищеварения при инфицировании SARS-CoV-2. Экспериментальная и клиническая гастроэнтерология. Экспериментальная и клиническая гастроэнтерология. 2020; 3: 4—9. [Stefanyuk O.V., Lazebnik L.B. The defeat of the digestive system during infection SARS-CoV-2. Eksperimental'naya i klinicheskaya gastroenterologiya. 2020; 3: 4—9 (In Russ.)]. doi: 10.31146/1682-8658-ecg-175-3-4-9.

  6. Jin X., Lian J.-S., Hu J.-H. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69(6): 1002—09. doi: 10.1136/gutjnl-2020-320926.

  7. Лазебник Л.Б., Радченко В.Г., Джадхав С.Н. с соавт. Системное воспаление и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2019; 5: 29—41. [Lazebnik L.B., Radchenko V.G., Gadhav S.N. et al. Systemic inflammation and nonalcoholic fatty liver disease. Eksperimental'naya i klinicheskaya gastroenterologiya. 2019; 5: 29—41 (In Russ.)]. doi: 10.31146/1682-8658-ecg-165-5-29-41.

  8. Максимов В.А., Торшин И.Ю., Чучалин А.Г. с соавт. Эффективность и безопасность полипептидного препарата (Лаеннек) в терапии COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020; 6: 56—65. [Maksimov V.A., Torshin I.Yu., Chuchalin A.G. et al. The effectiveness and safety of a polypeptide drug (Laennec) for the treatment of COVID-19. Eksperimental'naya i klinicheskaya gastroenterologiya. 2020; 6: 56—65 (In Russ.)]. doi: 10.31146/1682-8658-ecg-178-6-56-65.

  9. Novembrino C., Porcella A., Conte D. et al. Erythrocyte ferritin concentration: analytical performance of the immunoenzymatic IMx-Ferritin (Abbott) assay. Clin Chem Lab Med. 2005; 43(4): 449—53. doi:10.1515/ CCLM.2005.079.

  10. Ni M., Tian F.B., Xiang D.D., Yu B. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19. J Med Virol. 2020; 10.1002/jmv.26070. doi: 10.1002/jmv.26070.

  11. Торшин И.Ю., Громова О.А., Диброва Е.А. с соавт. Пептиды в составе препарата Лаеннек, потенцирующие его антивирусные эффекты в лечении атопического дерматита герпетической инфекции. Российский аллергологический журнал. 2018; 1—1: 82—90. [Torshin I.Yu., Gromova O.A., Dibrova E.A. et al. Peptides in the composition of the drug Laennec, potentiating its antiviral effects in the treatment of atopic dermatitis of herpes infection. Rossiysky allergologichesky zhurnal. 2018; 1—1: 82—90 (In Russ.)].

  12. Li L.-Q., Huang T., Wang Y.-Q. et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92(6): 577—83. doi: 10.1002/jmv.25757.

  13. Feng G., Zheng K.I., Yan Q.-Q. et al. COVID-19 and liver dysfunction: current insights and emergent. J Clin Transl Hepatol. 2020; 8(1): 18—24. doi: 10.14218/JCTH.2020.00018.

  14. Henry B.M., de Oliveira M.H.S., Benoit S. et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7): 1021—28. doi: 10.1515/cclm-2020-0369.

  15. Wang Z., Du Z., Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract. 2020; 164: 108214. doi: 10.1016/j.diabres.2020.108214.

  16. Masetti C., Generali E., Colapietro F. et al. High mortality in COVID-19 patients with mild respiratory disease. Eur J Clin Invest. 2020; e13314. doi:10.1111/eci.13314.

  17. Yang H., Yang L.C., Zhang R.T. et al. [Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes]. Beijing Da Xue Xue Bao Yi Xue Ban. 2020; 52(3): 420—24. doi: 10.19723/j.issn.1671-167X.2020.03.004.

  18. Торшин И.Ю., Громова О.А. Микронутриенты против коронавирусов (под ред. А.Г. Чучалина). М.: ГЭОТАР-Медиа, 2020; 112 с. [Torshin I.Yu., Gromova O.A. Micronutrients against coronaviruses (ed. by Chuchalin A.G.). M.: GEOTAR-Media, 2020; 112 p. (In Russ.)]. doi: 10.33029/9704-5818-1-MVC-2020-1-112.

  19. Cheng Y., Luo R., Wang K. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97(5): 829—38. doi: 10.1016/j.kint.2020.03.005.

  20. Zeng F., Huang Y., Guo Y. et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. 2020; 96: 467—74. doi: 10.1016/j.ijid.2020.05.055.

  21. Торшин И.Ю., Громова О.А. Мировой опыт использования гидролизатов плаценты человека в терапии. Экспериментальная и клиническая гастроэнтерология. 2019; 10: 79—89. [Torshin I.Yu., Gromova O.A. Worldwide experience of the therapeutic use of the human placental hydrolytes. Eksperimental'naya i klinicheskaya gastroenterologiya. 2019; 10: 79—89 (In Russ.)]. doi: 10.31146/1682-8658-ecg-170-10-79-89.

  22. Torshin I.Yu., Rudakov K.V. Topological data analysis in materials science: The case of high-temperature cuprate superconductors. Pattern recognition and image analysis. 2020; 30(2): 262—74. doi: 10.1134/S1054661820020157.

  23. Torshin I.Yu., Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognition and Image Analysis. 2019; 29(4): 654—67. doi: 10.1134/ S1054661819040175.


About the Autors

Valery A. Maksimov, MD, professor, professor of the Department of dietetics and nutrition of Russian Medical Academy of Continuing Postgraduate Education of the Ministry of Healthcare of Russia. Address: 115446, Moscow, 21 Kashirskoe highway. Tel.: +7 (499) 613-17-14. E-mail: dietologia.rmapo@gmail.com. ORCID: 0000-0003-4120-1071
Olga N. Tkacheva, MD, professor, Director of Gerontological Scientific and Clinical Center of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Chief freelance geriatrician of the Ministry of Healthcare of Russia. Address: 129226, Moscow, 16 1st Leonov Str. E-mail: rgnkc@rgnkc.ru. ORCID: 0000-0002-4193-688X
Irina D. Strazhesko, PhD, Deputy Director for translational medicine, head of the Laboratory for translational research in gerontology of Gerontological Scientific and Clinical Center of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 129226, Moscow, 16 1st Leonov Str. ORCID: 0000-0002-3657-0676
Ivan Yu. Torshin, PhD in physics and mathematics, PhD in chemistry, Senior researcher of Federal Research Center «Informatics and management» of Russian Academy of Sciences. Address: 119333, Moscow, 42 Vavilov Str. Tel.: +7 (499) 135-24-89. E-mail: info@pharmacoinformatics.ru. Scopus Author ID: 7003300274. RSCI SPIN-code: 1375-1114. Author ID: 54104. ORCID: 0000-0002-2659-7998. WOS ID: C-7683-2018
Olga A. Gromova, MD, professor, freelance research assistant, scientific director of Federal Research Center «Informatics and management» of Russian Academy of Sciences, Deputy Director for research of Russian Collaborating Center of the UNESCO Institute of Micronutrients, freelance research assistant of Big Data Storage and Analysis Center of Lomonosov Moscow State University. Address: 119333, Moscow, 42 Vavilov Str. Tel.: +7 (499) 135-24-89. SPIN-code: 6317-9833. Author ID: 94901. Scopus Author ID: 7003589812. ORCID: 0000-0002-7663-710X. WOS ID: J-4946-2017
Alexander G. Chuchalin, MD, professor, Academician of RAS, head of the Department of hospital therapy of pediatric Faculty of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 105077, Moscow, 32/61 11th Parkovaya Str. ORCID: 0000-0002-5070-5450
Leonid B. Lazebnik, MD, professor, professor of the Department of polyclinic therapy of Faculty of general medicine of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (985) 920-83-42. E-mail: leonid.borisl@gmail.com. ORCID: 0000-0001-8736-5851. Scopus ID: 7005446863

Back to Content

Бионика Медиа